×
About 390 results

ALLMedicine™ Alopecia Universalis Center

Research & Reviews  113 results

Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhib...
https://doi.org/10.1016/j.jaut.2022.102926
Journal of Autoimmunity; Paggioli I, Moss J

Nov 7th, 2022 - Alopecia Areata (AA) is a T-cell mediated autoimmune attack on hair follicles resulting in rapidly developing areas of hair loss involving the scalp and beard that can progress to total scalp hair loss (alopecia totalis) and loss of eyebrows, eyel...

Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Ar...
https://doi.org/10.1111/dth.15871
Dermatologic Therapy; Husein-ElAhmed H, Abdulla N et. al.

Oct 1st, 2022 - Tofacitinib is a pan-janus kinase inhibitor (JAK) which has been tested off-label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real-life setting is still poor. We evaluated long-term efficacy and safety of to...

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04011748

Sep 22nd, 2022 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

A first case of childhood chronic inflammatory demyelinating polyneuropathy associated ...
https://doi.org/10.1016/j.braindev.2022.08.001
Brain & Development; Okubo Y, Miyabayashi T et. al.

Aug 16th, 2022 - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired demyelinating disease of the peripheral nervous system with unknown etiology. Alopecia universalis, an advanced form of alopecia areata (AA), is a condition characterized by c...

A Study of KL130008 in Adults With Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05496426

Aug 11th, 2022 - This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).

see more →

Clinicaltrials.gov  13 results

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04011748

Sep 22nd, 2022 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

A Study of KL130008 in Adults With Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05496426

Aug 11th, 2022 - This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).

Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04238091

Mar 21st, 2022 - Alopecia areata (AA) is an autoimmune condition resulting in chronic and relapsing hair loss. AA patchy is associated with well-circumscribed patches of hair loss, commonly on the scalp or face, while alopecia totalis (AT) and alopecia universalis...

Fecal Transplant for Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04833179

Apr 6th, 2021 - Alopecia areata (AA) is a common autoimmune disease that triggers non scarring hair loss in different severities. Usually the hair loss will be contained to the scalp and / or beard, but in some cases, there will be total hair loss from the entire...

A Study of Secukinumab for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT02599129

Mar 11th, 2021 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

see more →

News  30 results

Unique Treatment for Alopecia Areata Combining Epinephrine With an Intralesional Steroid
https://www.mdedge.com/dermatology/article/256923/hair-nails/unique-treatment-alopecia-areata-combining-epinephrine
Eugeniu Stratulat, MD, Terri Shih, BS et. al.

Aug 9th, 2022 - Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss with preservation of the hair follicle (HF). The lifetime incidence risk of AA is approximately 2%,1 with a mean age of onset of 25 to 36 years and with no clinica.

Focal hair loss
https://www.mdedge.com/familymedicine/article/254363/dermatology/focal-hair-loss
MDedge Family Medicine;

May 5th, 2022 - The findings of smooth, round alopecia occurring rapidly without associated scarring, pain, or itching, is consistent with the diagnosis of alopecia areata. Alopecia areata is a common autoimmune disease caused by T lymphocytes targeting hair foll.

JAK Inhibitor Provides Impressive Hair Growth for Patients With Alopecia Areata
https://www.medscape.com/viewarticle/960162

Oct 4th, 2021 - Baricitinib, an oral inhibitor of Janus kinase (JAK) types 1 and 2, produced substantial rates of hair growth with acceptable tolerability for patients with alopecia areata, according to the results of two phase 3 trials presented at the European ...

Microbiome: Gut dysbiosis linked to development of alopecia areata
https://www.mdedge.com/dermatology/article/244445/hair-nails/microbiome-gut-dysbiosis-linked-development-alopecia-areata
Jeff Craven

Aug 19th, 2021 - Patients with alopecia areata (AA) appear to have a gut dysbiosis not seen in healthy individuals, according to research presented at the annual meeting of the Society for Investigative Dermatology. There have been reports of gut microbiome dysbio.

Remote-Onset Alopecia Areata Attributed to Ipilimumab
https://www.mdedge.com/dermatology/article/215086/hair-nails/remote-onset-alopecia-areata-attributed-ipilimumab
David R. Pearson, MD, Karl Lewis, MD et. al.

Jan 7th, 2020 - Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a key co-stimulatory receptor expressed on activated T cells that negatively regulates T-cell activation. 1-3 It exerts its effects in part by the prevention of IL-2 transcription and inhibiti.

see more →